Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population

Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population

HPV remains the most common sexually transmitted disease worldwide, despite improvements in awareness, screening, prophylactic vaccination uptake, and surgical treatment. VGX-3100 is an immunotherapy that uses electroporation to introduce DNA encoding for modified HPV-16 and HPV-18, E6-and E7 protei...

Full description

Bibliographic Details
Main Authors: Rebecca K. Hollenberg, Diane R. Krieger, Robert Samuels, Kim Kraynyak, Albert Sylvester, Matthew Morrow, Jean Boyer, Michael Dallas, Prakash K. Bhuyan
Format: Article
Language:English
Published: Taylor & Francis Group 2020-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunotherapy
dna
hpv
electroporation
Online Access:http://dx.doi.org/10.1080/21645515.2019.1695459

Internet

http://dx.doi.org/10.1080/21645515.2019.1695459

Similar Items